Paul E. McKeever
YOU?
Author Swipe
View article: A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection
A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection Open
Background High-grade gliomas are fatal with universally poor prognosis. Initiation of effective cancer immune responses requires functional immune cells, particularly afferent antigen-presenting cells, which are typically absent from the …
View article: Whole Exome Sequencing Identifies PHF14 Mutations in Neurocytoma and Predicts Responsivity to the PDGFR Inhibitor Sunitinib
Whole Exome Sequencing Identifies PHF14 Mutations in Neurocytoma and Predicts Responsivity to the PDGFR Inhibitor Sunitinib Open
Neurocytomas are rare low-grade brain tumors predominantly affecting young adults, but their cellular origin and molecular pathogenesis is largely unknown. We previously reported a sellar neurocytoma that secreted excess arginine vasopress…
View article: Clinical Reasoning: A 59-Year-Old Man With Progressive Proximal Weakness Since Childhood
Clinical Reasoning: A 59-Year-Old Man With Progressive Proximal Weakness Since Childhood Open
A 59-year-old man presented with slowly progressive weakness. During childhood, he had difficulty climbing stairs. At age 30 years, he noted difficulty getting out of a chair or standing up from the floor without using his arms. At age 48 …
View article: ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM
ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM Open
This is an interim report on a first in human Phase I dose escalation trial of the combination of two adenoviral vectors expressing HSV1-TK or Flt3L for the treatment of newly diagnosed, resectable malignant gliomas. Lack of dendritic cell…
View article: MON-129 An Unusual LMNA Mutation Causing a Complex Phenotype: When the Genetic Diagnosis Uncovers Novel Features
MON-129 An Unusual LMNA Mutation Causing a Complex Phenotype: When the Genetic Diagnosis Uncovers Novel Features Open
Background: Lipodystrophy syndromes are characterized by loss of body fat. Although classical Familial Partial Lipodystrophy (FPLD) and Congenital Generalized Lipodystrophy (CGL) have different clinical presentations, we have encountered a…
View article: Somatostatin Receptor Ligand Therapy—A Potential Therapy for Neurocytoma
Somatostatin Receptor Ligand Therapy—A Potential Therapy for Neurocytoma Open
To the best of our knowledge, we have described the first use of SRL therapy for an atypical NC. Our results support consideration of adjuvant SRL therapy for NC refractory to surgical removal. Our findings further raise the possibility of…
View article: Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors
Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors Open
Purpose Brain tumors have become the leading cause of cancer-related mortality in young patients. Novel effective therapies on the basis of the unique biology of each tumor are urgently needed. The goal of this study was to evaluate the fe…
View article: Anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme a reductase autoantibody‐positive necrotizing autoimmune myopathy with dermatomyositis‐like eruption
Anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme a reductase autoantibody‐positive necrotizing autoimmune myopathy with dermatomyositis‐like eruption Open
Peer Reviewed
View article: Molecular characterization reveals <i>NF1</i> deletions and <i>FGFR1</i>‐activating mutations in a pediatric spinal oligodendroglioma
Molecular characterization reveals <i>NF1</i> deletions and <i>FGFR1</i>‐activating mutations in a pediatric spinal oligodendroglioma Open
Pediatric spinal oligodendrogliomas are rare and aggressive tumors. They do not share the same molecular features of adult oligodendroglioma, and no previous reports have examined the molecular features of pediatric spinal oligodendrogliom…